Albert Bourla

I couldn’t be prouder. Today, we can begin to turn millions of Americans’ hopes into reality. We have worked tirelessly to make the impossible possible, steadfast in our belief that science will win.

The Pfizer-BioNTech COVID-19 vaccine has not been approved or licensed by the U.S. FDA, but has been authorized for emergency use by FDA, under an Emergency Use Authorization (EUA) to prevent Coronavirus Disease 2019 (COVID-19) for use in individuals 16 years of age and older. The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of this product unless the declaration is terminated or authorization revoked sooner. Please see EUA Fact Sheet at www.cvdvaccine.com.

Happy #NationalPetDay from my at-home office mate, Simba. Some may know, I practiced veterinary medicine in Greece and my Pfizer career began in the Animal Health Division. I’ve always been passionate about helping animals. Spending quality time with this guy, I’m reminded to appreciate the things that bring me joy.

This week, I had the incredible opportunity to meet with colleagues, scientists, entrepreneurs, students and policy makers in Israel. It has been a moving, humbling and inspiring trip – one I will not soon forget.

I began by meeting with our talented Pfizer Israel colleagues in Tel Aviv. I am grateful to them for the important work they are doing for patients in Israel and beyond. Thank you, Metin Hullu, for helping to arrange this memorable visit.

Once in Jerusalem, I went to Yad Vashem, the World Holocaust Remembrance Center, which is unlike any other place I have visited and an essential reminder of the consequences of diminishing the value of human life.

Wednesday’s Genesis Prize ceremony was one of the most humbling and awe-inspiring experiences of my life. I can hardly believe that I am joining a group of Genesis laureates that include world-renowned human rights advocate Natan Sharansky and philanthropist Robert Kraft, both of whom were in attendance for the celebration. Thank you to the Genesis Prize Foundation for a wonderful evening spent with some of the Jewish community’s most inspiring leaders.

I concluded the week by delivering the commencement address to the graduating Class of 2022 at the world-renowned Technion - Israel Institute of Technology. Researchers at Technion have advanced solutions for climate change, connective media, health technologies, and urban engineering – among other important areas. I have no doubt these students will be tomorrow’s leaders, driving innovations and breakthroughs that make the world a stronger, healthier, more equitable place.

Israel has changed a lot since I first visited the country 45 years ago, but one thing that has not changed is the Israeli spirit: bold, joyful, innovative, compassionate, and committed to excellence and equity – much like the values we share at Pfizer.

I’m deeply proud that Pfizer has been recognized as one of TIME’s 100 Most Influential Companies of 2024. This honor belongs to all of my colleagues, and it is a testament to what I see every day: their passion, brilliance and dedication to making the world a healthier place.

Thank you to our remarkable team, whose bold vision and relentless efforts are enabling us to have a transformative impact on human health.

https://lnkd.in/dFhzjRmc

#TIME100Companies #PfizerProud

It’s with mixed emotions that I tell you my good friend John Young, Pfizer’s Chief Business Officer, will retire in early 2022. With 34 years of service to Pfizer, John is a well-respected leader whose dedication and passion for helping patients and advancing our purpose has had a huge impact on our success. Please join me in thanking him for all he has done and congratulating him on his well-deserved retirement: https://lnkd.in/d26ZpGK

Fantastisk! I recently had the great pleasure of visiting our new Swedish office. It is located in Hagastaden, an area between the cities of Stockholm and Solna, which is being developed as a neighborhood with residences, workplaces and cultural attractions, as well as an ecosystem for life science researchers and businesses. The office’s proximity to renowned medical institutions like the Karolinska Institutet makes it ideal for meeting with patients, partners and other important collaborators in healthcare. Thank you, Pfizer Sweden colleagues, for making my visit so memorable!

Pfizer is putting unprecedented resources into the fight against cancer, and today we got to share that inspirational and uplifting story with hundreds of millions of people by blending iconic science and a legendary song. This song has been stuck in my head, not just because it’s so catchy, but also because it perfectly captures the spirit of our work.
 
Saving lives has always been the ultimate goal of the healthcare community. It’s what inspired Charles Pfizer and Charles Erhart to start this great company in Brooklyn, NY 175 years ago. As our new video shows, they—and our tens of thousands of colleagues who are leading the charge against cancer and other deadly diseases—are part of a long line of scientists and innovators whose contributions have unlocked inspiring new possibilities in drug discovery and genetics, and advanced the next scientific breakthroughs to conquer cancer.
 
Our mission is not just to extend patients’ lives, but to meaningfully improve them. Researchers at Pfizer are relentlessly working on a next generation of potential breakthroughs across cancer types and treatment modalities. Beyond the lab, we’re also working with partners to break down barriers to care. We’re not just focused on therapies to treat this disease, but also on community-based strategies that can achieve equitable health outcomes for all cancer patients.
 
For the extra point, I invite you to watch and share our video—and I invite you to join us in the fight against cancer at https://lnkd.in/euVKzzrs.
 
https://lnkd.in/e4frbw-K

I shared Pfizer’s Q3 financial results today. In addition to generating stellar financial performance, we have laid a strong foundation for future growth that will help enable us to continue delivering breakthroughs that change patients’ lives.

Over the next 18 months, we expect to have up to 19 new products or indications in the market – including the five for which we have already begun co-promotion or commercialization earlier this year. This would represent the most ever in Pfizer’s history! The majority of these were discovered in-house, and nearly all are for indications outside of COVID-19. Here are some examples of what we have in the works:

- Respiratory syncytial virus (RSV) is a contagious respiratory disease that affects about 64 million people per year globally, representing a significant unmet need—particularly in older adults and infants. In March, the US FDA granted Breakthrough Designation for our RSV vaccine candidate for individuals 60 years of age or older. We are also excited about positive data from our clinical trial to develop a potential maternal RSV vaccine that can be administered to pregnant women to help protect their infants from RSV disease after birth through the first six months of life. Subject to regulatory approval, by late 2023 or early 2024, we could have the only RSV maternal vaccine on the market, along with an RSV vaccine for older adults that is efficacious and is well-tolerated with no safety signals identified in the study.

- Ulcerative colitis (UC) is a chronic inflammatory bowel disease that affects an estimated 6 to 8 million people around the world. We recently shared positive Phase 3 data from our clinical trial evaluation a potential treatment for UC. Many UC patients never achieve or maintain remission, so we are excited to be able to potentially offer an additional treatment option in the US as soon as the second half of 2023, pending regulatory approval.

- Finally, we are tackling migraines, one of the most common neurological diseases that affects more than 1 billion people worldwide. Following our acquisition of Biohaven in early October, we aim to build the world’s leading portfolio of migraine treatments to help meet a range of patient needs for managing this often debilitating disease.

Patients remain our North Star. Each is a unique person with a unique story, and our hope is to have a positive impact on their stories.

https://lnkd.in/ezDGaXsZ

#PfizerProud $PFE

We are living in a time when science is increasingly demonstrating the ability to take on the world’s most devastating diseases. Unfortunately, there is a tremendous health equity gap in our world that determines which of us can access these innovations—and which of us cannot. With all we have learned and accomplished over the past two years, the time is now to begin closing this gap.

Today, I was honored to join His Excellency Paul Kagame, President of Rwanda, His Excellency Lazarus McCarthy Chakwera, President of Malawi, and Bill Gates, co-chair of the Bill & Melinda Gates Foundation, at the World Economic Forum to launch a new initiative for Pfizer. We are excited and proud of this first-of-its-kind initiative, called ‘An Accord for a Healthier World,’ which aims to greatly reduce health inequities by enabling greater access to all of Pfizer’s patented, high-quality medicines and vaccines—both current and future—for 1.2 billion people living in 45 lower-income countries. This includes all 27 low-income countries and 18 countries that have transitioned from low to lower-middle-income classification in the last 10 years.

Because we learned during the #COVID19 pandemic that supply is only the first step to reaching patients in need, we will collaborate with global health leaders to make improvements in areas like diagnosis, education, infrastructure, storage and more. We will also work together with Accord partners and participants to identify the systems and processes that limit or prevent access to quality healthcare in these countries and implement sustainable solutions to remove these barriers and strengthen health systems.

We recognize that no one company or government can reverse generations of inequity alone. Through this initiative, we hope to be a catalyst, leading other stakeholders to join and support this historic Accord. We invite other global health leaders and organizations to join us so that, together, we can create a healthier world—one where every human being has equitable access to medicines and vaccines, and the hope that comes along with them.

https://lnkd.in/gijJkYmP

#PfizerProud #GlobalHealth #HealthEquity #WEF22 #ScienceWillWin

Every year, I look forward to meeting our new cohort of Pfizer summer workers. Recently, I met with them to share some advice and insight from my own professional journey. It was a great discussion, and I was so impressed by their passion and talent. Here are some highlights.

#SummerWithPfizer #PfizerIntern  #SummerInternship

I’m #PfizerProud that our team has delivered another strong quarter of commercial performance. Our Q3 financial results show that our focus on execution excellence is paying off, with market share gains in the US and internationally, as well as impressive growth. Some key highlights:

- Oncology, which now includes legacy Seagen products, grew an impressive 31% YOY with solid demand across our portfolio. For example, our antiandrogen treatment for prostate cancer is the market leader for four types of advanced prostate cancer and grew 28% YOY.

- We've made great progress on new product launches. Our oral treatment for migraine, for instance, saw 28% total prescription growth and continued leadership in this class of treatments (oral CGRP), capturing 85% of first-time CGRP prescriptions in primary care.

- We continue to strengthen our leadership in vaccines. For example, our pneumococcal conjugate vaccine has already achieved 83% market share in pediatrics and 97% in adults in the US. The recent #ACIP recommendation to expand adult pneumococcal vaccination to include adults 50 and older further positions us for continued success.

These commercial achievements combined with the impressive advancement of our pipeline wouldn’t be possible without the tireless efforts of our entire Pfizer team. So far this year, we have reached more than 271 million* people with our medicines and vaccines, and I am confident that we are well-positioned to build on this momentum to keep delivering for patients around the world.

https://lnkd.in/evvz-988

*Patient counts are estimates derived from multiple data sources.

$PFE